Data / Form D filings / EXCELLOS, Inc
EXCELLOS, Inc: Form D filings
EXCELLOS, Inc, a biotechnology company in San Diego, CA, filed 2 Form D notices with the SEC between 2021 and 2023. The latest, on August 16, 2023, reports $5 million sold of a $7 million offering to 1 investor.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 1155 ISLAND AVE, SUITE 250, San Diego, CA, 92101
- Phone
- (858) 472-8732
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Year incorporated
- 2020
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(c)
- SEC identifier (CIK)
- 1895465
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Aug 16, 2023 | New notice | $7,000,000 | $4,999,999 | $2,000,001 | 1 | Aug 1, 2023 | sec.gov |
| Nov 24, 2021 | New notice | $15,000,001 | $15,000,001 | 1 | Nov 5, 2021 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Terance Kinninger | Director | |
| Deval Lashkari, Ph.D. | Director | |
| David Wellis, Ph.D. | Executive Officer, Director | |
| Robert Finzi | Director | |
| Paul Grossman, Ph.D. | Director |
Other biotechnology companies in California that filed recently
- Trellis Bioscience, Inc. $9.1 million · Oct 29, 2026
- BigHat Biosciences, Inc. $75.1 million · Oct 26, 2026
- Theravie Pharma, Inc. $750,000 · Oct 19, 2026
- Adela, Inc. $12 million · Oct 19, 2026
- Estuary Biotherapeutics, Inc. $40.7 million · Oct 16, 2026
- Renue Life Sciences, Inc. $250,000 · Oct 14, 2026
Every Form D from the week of Aug 14, 2023 · All recent filings in California · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what EXCELLOS, Inc reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.